Anafranil (clomipramine) dosing, indications, interactions, adverse effects, and more (2023)

abametapir will increase the level or effect of clomipramine by affecting hepatic enzyme CYP1A2 metabolism. Avoid or Use Alternate Drug. For 2 weeks after abametapir application, avoid taking drugs that are CYP1A2 substrates. If not feasible, avoid use of abametapir.

adagrasib, clomipramine.Either increases effects of the other by QTc interval. Avoid or Use Alternate Drug. Each drug prolongs the QTc interval, which may increased the risk of Torsade de pointes, other serious arryhthmias, and sudden death. If coadministration unavoidable, more frequent monitoring is recommended for such patients.

clomipramine, albuterol. Other (see comment). Avoid or Use Alternate Drug. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.

clomipramine and amiodarone both increase QTc interval. Avoid or Use Alternate Drug.

amitriptyline and clomipramine both increase QTc interval. Avoid or Use Alternate Drug.amitriptyline and clomipramine both increase serotonin levels. Avoid or Use Alternate Drug.

amoxapine and clomipramine both increase QTc interval. Avoid or Use Alternate Drug.amoxapine and clomipramine both increase serotonin levels. Avoid or Use Alternate Drug.

apalutamide will decrease the level or effect of clomipramine by affecting hepatic enzyme CYP2C19 metabolism. Avoid or Use Alternate Drug. Coadministration of apalutamide, a strong CYP2C19 inducer, with drugs that are CYP2C19 substrates can result in lower exposure to these medications. Avoid or substitute another drug for these medications when possible. Evaluate for loss of therapeutic effect if medication must be coadministered.

clomipramine, arformoterol. Other (see comment). Avoid or Use Alternate Drug. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.

clomipramine and arsenic trioxide both increase QTc interval. Avoid or Use Alternate Drug.

clomipramine and artemether/lumefantrine both increase QTc interval. Avoid or Use Alternate Drug.

benzhydrocodone/acetaminophen and clomipramine both increase sedation. Avoid or Use Alternate Drug. Limit use to patients for whom alternative treatment options are inadequate

clomipramine, benzphetamine. Other (see comment). Avoid or Use Alternate Drug. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.

buprenorphine and clomipramine both increase QTc interval. Avoid or Use Alternate Drug.

buprenorphine buccal and clomipramine both increase QTc interval. Avoid or Use Alternate Drug.

buprenorphine subdermal implant and clomipramine both increase QTc interval. Avoid or Use Alternate Drug.buprenorphine subdermal implant and clomipramine both increase sedation. Avoid or Use Alternate Drug. Limit use to patients for whom alternative treatment options are inadequate

buprenorphine transdermal and clomipramine both increase QTc interval. Avoid or Use Alternate Drug.buprenorphine transdermal and clomipramine both increase sedation. Avoid or Use Alternate Drug. Limit use to patients for whom alternative treatment options are inadequate

buprenorphine, long-acting injection and clomipramine both increase QTc interval. Avoid or Use Alternate Drug.

bupropion will increase the level or effect of clomipramine by affecting hepatic enzyme CYP2D6 metabolism. Avoid or Use Alternate Drug.

clomipramine and buspirone both increase serotonin levels. Avoid or Use Alternate Drug.

clomipramine, calcium/magnesium/potassium/sodium oxybates.Either increases effects of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Profound sedation, respiratory depression, coma, and death may result if coadministered. Reserve concomitant prescribing of these drugs in patients for whom other treatment options are inadequate. Limit dosages and durations to the minimum required. Monitor closely for signs of respiratory depression and sedation.

chlorpromazine and clomipramine both increase QTc interval. Avoid or Use Alternate Drug.

ciprofloxacin will increase the level or effect of clomipramine by affecting hepatic enzyme CYP1A2 metabolism. Avoid or Use Alternate Drug. Concurrent use of drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias. It is important to monitor therapy carefully.

citalopram and clomipramine both increase serotonin levels. Avoid or Use Alternate Drug. Citalopram may increase TCA levels. Increased risk of serotonin syndrome or neuroleptic malignant syndrome. Potential risk for QT prolongation. ECG monitoring is recommended.citalopram and clomipramine both increase QTc interval. Avoid or Use Alternate Drug.

clarithromycin will increase the level or effect of clomipramine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.clomipramine and clarithromycin both increase QTc interval. Avoid or Use Alternate Drug.

clomipramine decreases effects of clonidine by Other (see comment). Avoid or Use Alternate Drug. Comment: Inhibition of uptake by adrenergic neurons.

clomipramine and cyclobenzaprine both increase serotonin levels. Avoid or Use Alternate Drug.

dacomitinib will increase the level or effect of clomipramine by affecting hepatic enzyme CYP2D6 metabolism. Avoid or Use Alternate Drug. Avoid use with CYP2D6 substrates where minimal increases in concentration of the CYP2D6 substrate may lead to serious or life-threatening toxicities.

dasatinib will increase the level or effect of clomipramine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.

degarelix and clomipramine both increase QTc interval. Avoid or Use Alternate Drug.

clomipramine and desipramine both increase QTc interval. Avoid or Use Alternate Drug.clomipramine and desipramine both increase serotonin levels. Avoid or Use Alternate Drug.

clomipramine and desvenlafaxine both increase serotonin levels. Avoid or Use Alternate Drug.

clomipramine, dexfenfluramine. Other (see comment). Avoid or Use Alternate Drug. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.

clomipramine, dexmethylphenidate. Other (see comment). Avoid or Use Alternate Drug. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.

clomipramine, dextroamphetamine. Other (see comment). Avoid or Use Alternate Drug. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.

clomipramine and dextromethorphan both increase serotonin levels. Avoid or Use Alternate Drug.

clomipramine, diethylpropion. Other (see comment). Avoid or Use Alternate Drug. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.

clomipramine, dobutamine. Other (see comment). Avoid or Use Alternate Drug. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.

clomipramine and dofetilide both increase QTc interval. Avoid or Use Alternate Drug.dofetilide increases toxicity of clomipramine by QTc interval. Avoid or Use Alternate Drug.

dolasetron, clomipramine.Either increases toxicity of the other by serotonin levels. Avoid or Use Alternate Drug.

clomipramine, dopamine. Other (see comment). Avoid or Use Alternate Drug. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.

clomipramine, dopexamine. Other (see comment). Avoid or Use Alternate Drug. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.

clomipramine and dosulepin both increase QTc interval. Avoid or Use Alternate Drug.clomipramine and dosulepin both increase serotonin levels. Avoid or Use Alternate Drug.

clomipramine and doxepin both increase QTc interval. Avoid or Use Alternate Drug.clomipramine and doxepin both increase serotonin levels. Avoid or Use Alternate Drug.

clomipramine and dronedarone both increase QTc interval. Avoid or Use Alternate Drug.

clomipramine and droperidol both increase QTc interval. Avoid or Use Alternate Drug.

duloxetine will increase the level or effect of clomipramine by affecting hepatic enzyme CYP2D6 metabolism. Avoid or Use Alternate Drug.duloxetine and clomipramine both increase serotonin levels. Avoid or Use Alternate Drug.

encorafenib and clomipramine both increase QTc interval. Avoid or Use Alternate Drug.

clomipramine, ephedrine. Other (see comment). Avoid or Use Alternate Drug. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.

epinephrine and clomipramine both increase QTc interval. Avoid or Use Alternate Drug.clomipramine, epinephrine. Other (see comment). Avoid or Use Alternate Drug. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.

epinephrine racemic and clomipramine both increase QTc interval. Avoid or Use Alternate Drug.clomipramine, epinephrine racemic. Other (see comment). Avoid or Use Alternate Drug. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.

erythromycin base will increase the level or effect of clomipramine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.clomipramine and erythromycin base both increase QTc interval. Avoid or Use Alternate Drug.

erythromycin ethylsuccinate will increase the level or effect of clomipramine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.clomipramine and erythromycin ethylsuccinate both increase QTc interval. Avoid or Use Alternate Drug.

erythromycin lactobionate will increase the level or effect of clomipramine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.clomipramine and erythromycin lactobionate both increase QTc interval. Avoid or Use Alternate Drug.

erythromycin stearate will increase the level or effect of clomipramine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.clomipramine and erythromycin stearate both increase QTc interval. Avoid or Use Alternate Drug.

escitalopram and clomipramine both increase serotonin levels. Avoid or Use Alternate Drug.

clomipramine, fenfluramine. Other (see comment). Avoid or Use Alternate Drug. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.

fexinidazole and clomipramine both increase QTc interval. Avoid or Use Alternate Drug. Avoid coadministration of fexinidazole with drugs known to block potassium channels or prolong QT interval.

fluconazole will increase the level or effect of clomipramine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.clomipramine and fluconazole both increase QTc interval. Avoid or Use Alternate Drug.

fluoxetine will increase the level or effect of clomipramine by affecting hepatic enzyme CYP2D6 metabolism. Avoid or Use Alternate Drug.fluoxetine and clomipramine both increase serotonin levels. Avoid or Use Alternate Drug.

fluphenazine and clomipramine both increase QTc interval. Avoid or Use Alternate Drug.

fluvoxamine and clomipramine both increase serotonin levels. Avoid or Use Alternate Drug.

clomipramine and formoterol both increase QTc interval. Avoid or Use Alternate Drug.clomipramine, formoterol. Other (see comment). Avoid or Use Alternate Drug. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.

fosamprenavir increases levels of clomipramine by decreasing metabolism. Avoid or Use Alternate Drug.

givosiran will increase the level or effect of clomipramine by affecting hepatic enzyme CYP1A2 metabolism. Avoid or Use Alternate Drug. Avoid coadministration of sensitive CYP1A2 substrates with givosiran. If unavoidable, decrease the CYP1A2 substrate dosage in accordance with approved product labeling.givosiran will increase the level or effect of clomipramine by affecting hepatic enzyme CYP2D6 metabolism. Avoid or Use Alternate Drug. Avoid coadministration of sensitive CYP2D6 substrates with givosiran. If unavoidable, decrease the CYP2D6 substrate dosage in accordance with approved product labeling.

granisetron, clomipramine.Either increases toxicity of the other by serotonin levels. Avoid or Use Alternate Drug.granisetron and clomipramine both increase QTc interval. Avoid or Use Alternate Drug.

clomipramine decreases effects of guanfacine by Other (see comment). Avoid or Use Alternate Drug. Comment: Inhibition of uptake by adrenergic neurons.

haloperidol will increase the level or effect of clomipramine by affecting hepatic enzyme CYP2D6 metabolism. Avoid or Use Alternate Drug.clomipramine and haloperidol both increase QTc interval. Avoid or Use Alternate Drug.

hydroxychloroquine sulfate and clomipramine both increase QTc interval. Avoid or Use Alternate Drug.

clomipramine and imipramine both increase QTc interval. Avoid or Use Alternate Drug.clomipramine and imipramine both increase serotonin levels. Avoid or Use Alternate Drug.

clomipramine will decrease the level or effect of iobenguane I 131 by Other (see comment). Avoid or Use Alternate Drug. Based on the mechanism of action of iobenguane, drugs that reduce catecholamine uptake or that deplete catecholamine stores may interfere with iobenguane uptake into cells, and thus, reduce iobenguane efficacy. Discontinue interfering drugs for at least 5 half-lives before administration of either the dosimetry or an iobenguane dose. Do not administer these drugs until at least 7 days after each iobenguane dose.

clomipramine, isoproterenol. Other (see comment). Avoid or Use Alternate Drug. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.

ivosidenib and clomipramine both increase QTc interval. Avoid or Use Alternate Drug. Avoid coadministration of QTc prolonging drugs with ivosidenib or replace with alternate therapies. If coadministration of a QTc prolonging drug is unavoidable, monitor for increased risk of QTc interval prolongation.

clomipramine and ketoconazole both increase QTc interval. Avoid or Use Alternate Drug.

leniolisib will increase the level or effect of clomipramine by affecting hepatic enzyme CYP1A2 metabolism. Avoid or Use Alternate Drug. Avoid leniolisib with CYP1A2 substrates that have a narrow therapeutic index

clomipramine, levalbuterol. Other (see comment). Avoid or Use Alternate Drug. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.

clomipramine and levoketoconazole both increase QTc interval. Avoid or Use Alternate Drug.

levomilnacipran and clomipramine both increase serotonin levels. Avoid or Use Alternate Drug.

linezolid and clomipramine both increase serotonin levels. Avoid or Use Alternate Drug. Linezolid may increase serotonin as a result of MAO-A inhibition. If linezolid must be administered, discontinue serotonergic drug immediately and monitor for CNS toxicity. Serotonergic therapy may be resumed 24 hours after last linezolid dose or after 2 weeks of monitoring, whichever comes first.

clomipramine, lisdexamfetamine. Other (see comment). Avoid or Use Alternate Drug. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.

clomipramine and lofepramine both increase QTc interval. Avoid or Use Alternate Drug.clomipramine and lofepramine both increase serotonin levels. Avoid or Use Alternate Drug.

lonafarnib will increase the level or effect of clomipramine by affecting hepatic enzyme CYP2C19 metabolism. Avoid or Use Alternate Drug. Lonafarnib may increase the AUC and peak concentration of CYP2C19 substrates. If coadministration unavoidable, monitor for adverse reactions and reduce the CYP2C19 substrate dose in accordance with its approved product labeling.

clomipramine and lorcaserin both increase serotonin levels. Avoid or Use Alternate Drug.

clomipramine and lumefantrine both increase QTc interval. Avoid or Use Alternate Drug.

macimorelin and clomipramine both increase QTc interval. Avoid or Use Alternate Drug. Macimorelin causes an increase of ~11 msec in the corrected QT interval. Avoid coadministration with drugs that prolong QT interval, which could increase risk for developing torsade de pointes-type ventricular tachycardia. Allow sufficient washout time of drugs that are known to prolong the QT interval before administering macimorelin.

clomipramine and maprotiline both increase QTc interval. Avoid or Use Alternate Drug.clomipramine and maprotiline both increase serotonin levels. Avoid or Use Alternate Drug.

mefloquine increases toxicity of clomipramine by QTc interval. Avoid or Use Alternate Drug. Mefloquine may enhance the QTc prolonging effect of high risk QTc prolonging agents.

clomipramine and meperidine both increase serotonin levels. Avoid or Use Alternate Drug.

clomipramine, metaproterenol. Other (see comment). Avoid or Use Alternate Drug. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.

clomipramine, methamphetamine. Other (see comment). Avoid or Use Alternate Drug. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.

methylene blue and clomipramine both increase serotonin levels. Avoid or Use Alternate Drug. Methylene blue may increase serotonin as a result of MAO-A inhibition. If methylene blue must be administered, discontinue serotonergic drug immediately and monitor for CNS toxicity. Serotonergic therapy may be resumed 24 hours after last methylene blue dose or after 2 weeks of monitoring, whichever comes first.

clomipramine, methylenedioxymethamphetamine. Other (see comment). Avoid or Use Alternate Drug. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.

clomipramine, metoclopramide intranasal.Either increases effects of the other by Other (see comment). Avoid or Use Alternate Drug. Comment: Avoid use of metoclopramide intranasal or interacting drug, depending on importance of drug to patient.

clomipramine, midodrine. Other (see comment). Avoid or Use Alternate Drug. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.

milnacipran and clomipramine both increase serotonin levels. Avoid or Use Alternate Drug.

mirtazapine and clomipramine both increase QTc interval. Avoid or Use Alternate Drug.

mobocertinib and clomipramine both increase QTc interval. Avoid or Use Alternate Drug. If coadministration unavoidable, reduce mobocertinib dose and monitor QTc interval more frequently.

clomipramine and moxifloxacin both increase QTc interval. Avoid or Use Alternate Drug.

nefazodone will increase the level or effect of clomipramine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.nefazodone and clomipramine both increase serotonin levels. Avoid or Use Alternate Drug.

netupitant/palonosetron, clomipramine.Either increases toxicity of the other by serotonin levels. Avoid or Use Alternate Drug.

clomipramine and nilotinib both increase QTc interval. Avoid or Use Alternate Drug.

clomipramine, norepinephrine. Other (see comment). Avoid or Use Alternate Drug. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.

clomipramine and nortriptyline both increase QTc interval. Avoid or Use Alternate Drug.clomipramine and nortriptyline both increase serotonin levels. Avoid or Use Alternate Drug.

clomipramine and octreotide both increase QTc interval. Avoid or Use Alternate Drug.

clomipramine and octreotide (Antidote) both increase QTc interval. Avoid or Use Alternate Drug.

clomipramine and olopatadine intranasal both increase sedation. Avoid or Use Alternate Drug. Coadministration increases risk of CNS depression, which can lead to additive impairment of psychomotor performance and cause daytime impairment.

clomipramine and ondansetron both increase QTc interval. Avoid or Use Alternate Drug. Avoid with congenital long QT syndrome; ECG monitoring recommended with concomitant medications that prolong QT interval, electrolyte abnormalities, CHF, or bradyarrhythmias.ondansetron, clomipramine.Either increases toxicity of the other by serotonin levels. Avoid or Use Alternate Drug.

ozanimod increases toxicity of clomipramine by sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Avoid or Use Alternate Drug. Because the active metabolite of ozanimod inhibits MAO-B in vitro, there is a potential for serious adverse reactions, including hypertensive crisis. Therefore, coadministration of ozanimod with drugs that can increase norepinephrine or serotonin is not recommended. Monitor for hypertension with concomitant use.

palonosetron, clomipramine.Either increases toxicity of the other by serotonin levels. Avoid or Use Alternate Drug.

paroxetine will increase the level or effect of clomipramine by affecting hepatic enzyme CYP2D6 metabolism. Avoid or Use Alternate Drug.paroxetine and clomipramine both increase serotonin levels. Avoid or Use Alternate Drug.

pefloxacin will increase the level or effect of clomipramine by affecting hepatic enzyme CYP1A2 metabolism. Avoid or Use Alternate Drug.

perphenazine and clomipramine both increase QTc interval. Avoid or Use Alternate Drug.

clomipramine, phendimetrazine. Other (see comment). Avoid or Use Alternate Drug. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.

clomipramine, phentermine. Other (see comment). Avoid or Use Alternate Drug. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.

clomipramine, phenylephrine. Other (see comment). Avoid or Use Alternate Drug. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.

clomipramine, phenylephrine PO. Other (see comment). Avoid or Use Alternate Drug. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.

clomipramine, pirbuterol. Other (see comment). Avoid or Use Alternate Drug. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.

clomipramine decreases effects of pitolisant by Other (see comment). Avoid or Use Alternate Drug. Comment: Pitolisant increases histamine levels in the brain; therefore, H1 receptor antagonists that cross the blood-brain barrier may reduce the efficacy of pitolisant.

promazine and clomipramine both increase QTc interval. Avoid or Use Alternate Drug.

promethazine and clomipramine both increase QTc interval. Avoid or Use Alternate Drug.

clomipramine, propylhexedrine. Other (see comment). Avoid or Use Alternate Drug. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.

clomipramine and protriptyline both increase QTc interval. Avoid or Use Alternate Drug.clomipramine and protriptyline both increase serotonin levels. Avoid or Use Alternate Drug.

clomipramine increases effects of pseudoephedrine by sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Avoid or Use Alternate Drug. Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.

quinidine will increase the level or effect of clomipramine by affecting hepatic enzyme CYP2D6 metabolism. Avoid or Use Alternate Drug.

rasagiline and clomipramine both increase serotonin levels. Avoid or Use Alternate Drug. Avoid combination within 14 days of MAOI use.

ribociclib increases toxicity of clomipramine by QTc interval. Avoid or Use Alternate Drug.

clomipramine, salmeterol. Other (see comment). Avoid or Use Alternate Drug. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.

selegiline transdermal and clomipramine both increase serotonin levels. Avoid or Use Alternate Drug.

selinexor, clomipramine. unspecified interaction mechanism. Avoid or Use Alternate Drug. Patients treated with selinexor may experience neurological toxicities. Avoid taking selinexor with other medications that may cause dizziness or confusion.

clomipramine, serdexmethylphenidate/dexmethylphenidate. Other (see comment). Avoid or Use Alternate Drug. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.

sertraline and clomipramine both increase serotonin levels. Avoid or Use Alternate Drug.sertraline and clomipramine both increase QTc interval. Avoid or Use Alternate Drug.

clomipramine, sodium oxybate.Either increases effects of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Profound sedation, respiratory depression, coma, and death may result if coadministered. Reserve concomitant prescribing of these drugs in patients for whom other treatment options are inadequate. Limit dosages and durations to the minimum required. Monitor closely for signs of respiratory depression and sedation.

clomipramine and St John's Wort both increase serotonin levels. Avoid or Use Alternate Drug.

tedizolid, clomipramine.Either increases effects of the other by Mechanism: pharmacodynamic synergism. Avoid or Use Alternate Drug. both increase serotonin levels; increased risk of serotonin syndrome.

clomipramine, terbutaline. Other (see comment). Avoid or Use Alternate Drug. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.

thioridazine and clomipramine both increase QTc interval. Avoid or Use Alternate Drug.

clomipramine and toremifene both increase QTc interval. Avoid or Use Alternate Drug. Concurrent use of toremifene with agents causing QT prolongation should be avoided. If concomitant use is required it's recommended that toremifene be interrupted. If interruption not possible, patients requiring therapy with a drug that prolongs QT should be closely monitored. ECGs should be obtained for high risk patients.

clomipramine and trazodone both increase QTc interval. Avoid or Use Alternate Drug.trazodone and clomipramine both increase serotonin levels. Avoid or Use Alternate Drug.

trifluoperazine and clomipramine both increase QTc interval. Avoid or Use Alternate Drug.

clomipramine and trimipramine both increase QTc interval. Avoid or Use Alternate Drug.clomipramine and trimipramine both increase serotonin levels. Avoid or Use Alternate Drug.

clomipramine increases toxicity of umeclidinium bromide/vilanterol inhaled by QTc interval. Avoid or Use Alternate Drug. Exercise extreme caution when vilanterol coadministered with drugs that prolong QTc interval; adrenergic agonist effects on the cardiovascular system may be potentiated.clomipramine and umeclidinium bromide/vilanterol inhaled both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Avoid or Use Alternate Drug. Exercise extreme caution if vilanterol coadministered with MAOIs or TCAs, or within 2 weeks of discontinuation of these drugs; adrenergic agonist effects on the cardiovascular system may be potentiated

clomipramine, vandetanib.Either increases toxicity of the other by QTc interval. Avoid or Use Alternate Drug. Avoid coadministration with drugs known to prolong QT interval; if a drug known to prolong QT interval must be used, more frequent ECG monitoring is recommended.

vemurafenib and clomipramine both increase QTc interval. Avoid or Use Alternate Drug. Concomitant use of vemurafenib with drugs that prolong QT interval is not recommended.

venlafaxine and clomipramine both increase serotonin levels. Avoid or Use Alternate Drug.

clomipramine and vilanterol/fluticasone furoate inhaled both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Avoid or Use Alternate Drug. Exercise extreme caution if vilanterol coadministered with MAOIs or TCAs, or within 2 weeks of discontinuation of these drugs; adrenergic agonist effects on the cardiovascular system may be potentiatedclomipramine increases toxicity of vilanterol/fluticasone furoate inhaled by QTc interval. Avoid or Use Alternate Drug. Exercise extreme caution when vilanterol coadministered with drugs that prolong QTc interval; adrenergic agonist effects on the cardiovascular system may be potentiated.

clomipramine, vilazodone.Either increases toxicity of the other by serotonin levels. Avoid or Use Alternate Drug. Concomitant therapy should be discontinued immediately if signs or symptoms of serotonin syndrome emerge and supportive symptomatic treatment should be initiated. .

clomipramine, vortioxetine.Either increases effects of the other by serotonin levels. Avoid or Use Alternate Drug.

clomipramine, xylometazoline. Other (see comment). Avoid or Use Alternate Drug. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.

yohimbe, clomipramine. Mechanism: unspecified interaction mechanism. Contraindicated. May cause increase or decrease in blood pressure.

clomipramine, yohimbine. Other (see comment). Avoid or Use Alternate Drug. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.

clomipramine and ziprasidone both increase QTc interval. Avoid or Use Alternate Drug.

clomipramine and 5-HTP both increase serotonin levels. Modify Therapy/Monitor Closely.

abiraterone increases levels of clomipramine by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor. Avoid coadministration of abiraterone with substrates of CYP2D6. If alternative therapy cannot be used, exercise caution and consider a dose reduction of the CYP2D6 substrate.

abobotulinumtoxinA increases effects of clomipramine by pharmacodynamic synergism. Use Caution/Monitor. Use of anticholinergic drugs after administration of botulinum toxin-containing products may potentiate systemic anticholinergic effects. .

clomipramine, aceclofenac.Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. Clomipramine inhib. serotonin uptake by platelets.

clomipramine, acemetacin.Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. Clomipramine inhib. serotonin uptake by platelets.

aclidinium and clomipramine both decrease cholinergic effects/transmission. Use Caution/Monitor.

acrivastine and clomipramine both increase sedation. Use Caution/Monitor.

clomipramine increases and albuterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

alfentanil and clomipramine both increase sedation. Use Caution/Monitor.

clomipramine and alfuzosin both increase QTc interval. Use Caution/Monitor.

almotriptan and clomipramine both increase serotonin levels. Modify Therapy/Monitor Closely.

alprazolam and clomipramine both increase sedation. Use Caution/Monitor.

clomipramine increases toxicity of amifampridine by Other (see comment). Modify Therapy/Monitor Closely. Comment: Amifampridine can cause seizures. Coadministration with drugs that lower seizure threshold may increase this risk.

amiodarone will increase the level or effect of clomipramine by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.

clomipramine and amisulpride both increase QTc interval. Use Caution/Monitor. ECG monitoring is recommended if coadministered.

amitriptyline and clomipramine both decrease cholinergic effects/transmission. Use Caution/Monitor.amitriptyline and clomipramine both increase sedation. Use Caution/Monitor.

amobarbital will decrease the level or effect of clomipramine by affecting hepatic enzyme CYP1A2 metabolism. Use Caution/Monitor.amobarbital will decrease the level or effect of clomipramine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely.amobarbital and clomipramine both increase sedation. Use Caution/Monitor.

amoxapine and clomipramine both decrease cholinergic effects/transmission. Use Caution/Monitor.amoxapine and clomipramine both increase sedation. Use Caution/Monitor.

anagrelide and clomipramine both increase QTc interval. Use Caution/Monitor.

anticholinergic/sedative combos and clomipramine both decrease cholinergic effects/transmission. Use Caution/Monitor.

clomipramine and apomorphine both increase sedation. Use Caution/Monitor.

aprepitant will increase the level or effect of clomipramine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.

clomipramine increases and arformoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

aripiprazole and clomipramine both increase sedation. Use Caution/Monitor.aripiprazole and clomipramine both increase QTc interval. Use Caution/Monitor.

armodafinil will decrease the level or effect of clomipramine by affecting hepatic enzyme CYP1A2 metabolism. Use Caution/Monitor.clomipramine increases and armodafinil decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

asenapine will increase the level or effect of clomipramine by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.asenapine and clomipramine both increase QTc interval. Use Caution/Monitor.asenapine and clomipramine both increase sedation. Use Caution/Monitor.

asenapine transdermal and clomipramine both increase QTc interval. Use Caution/Monitor.asenapine transdermal and clomipramine both increase sedation. Use Caution/Monitor.

clomipramine, aspirin.Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. Clomipramine inhib. serotonin uptake by platelets.

clomipramine, aspirin rectal.Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. Clomipramine inhib. serotonin uptake by platelets.

clomipramine, aspirin/citric acid/sodium bicarbonate.Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. Clomipramine inhib. serotonin uptake by platelets.

atazanavir will increase the level or effect of clomipramine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.atazanavir increases levels of clomipramine by unspecified interaction mechanism. Use Caution/Monitor.

clomipramine increases levels of atomoxetine by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.atomoxetine and clomipramine both increase QTc interval. Use Caution/Monitor.

atracurium and clomipramine both decrease cholinergic effects/transmission. Use Caution/Monitor.

atropine and clomipramine both decrease cholinergic effects/transmission. Use Caution/Monitor.

atropine IV/IM and clomipramine both decrease cholinergic effects/transmission. Use Caution/Monitor.

avapritinib and clomipramine both increase sedation. Use Caution/Monitor.

azelastine and clomipramine both increase sedation. Use Caution/Monitor.

clomipramine and azithromycin both increase QTc interval. Use Caution/Monitor.

baclofen and clomipramine both increase sedation. Use Caution/Monitor.

clomipramine and bedaquiline both increase QTc interval. Modify Therapy/Monitor Closely. ECG should be monitored closely

belladonna alkaloids and clomipramine both decrease cholinergic effects/transmission. Use Caution/Monitor.

belladonna and opium and clomipramine both decrease cholinergic effects/transmission. Use Caution/Monitor.belladonna and opium and clomipramine both increase sedation. Use Caution/Monitor.

clomipramine, benazepril.Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Increases risk of hypotension.

benperidol and clomipramine both increase sedation. Use Caution/Monitor.

benzhydrocodone/acetaminophen, clomipramine.Either increases effects of the other by serotonin levels. Use Caution/Monitor. Coadministration of drugs that affect the serotonergic neurotransmitter system may result in serotonin syndrome. If concomitant use is warranted, carefully observe the patient, particularly during treatment initiation and dose adjustment.

clomipramine increases and benzphetamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

benztropine and clomipramine both decrease cholinergic effects/transmission. Use Caution/Monitor.

bethanechol increases and clomipramine decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.

clomipramine will increase the level or effect of brexpiprazole by affecting hepatic enzyme CYP2D6 metabolism. Modify Therapy/Monitor Closely. Administer a quarter of brexpiprazole dose if coadministered with a moderate CYP2D6 inhibitor PLUS a strong/moderate CYP3A4 inhibitor. brexpiprazole and clomipramine both increase sedation. Use Caution/Monitor.

brimonidine and clomipramine both increase sedation. Use Caution/Monitor.

brivaracetam and clomipramine both increase sedation. Use Caution/Monitor.

brompheniramine and clomipramine both increase sedation. Use Caution/Monitor.

buprenorphine and clomipramine both increase sedation. Use Caution/Monitor.

buprenorphine buccal and clomipramine both increase sedation. Use Caution/Monitor.

clomipramine, buprenorphine subdermal implant.Either increases toxicity of the other by serotonin levels. Use Caution/Monitor. Concomitant use could result in life-threatening serotonin syndrome. If concomitant use is warranted, carefully observe the patient, particularly during treatment initiation, and during dose adjustment of the serotonergic drug. Discontinue buprenorphine if serotonin syndrome is suspected.

clomipramine, buprenorphine, long-acting injection.Either increases toxicity of the other by serotonin levels. Use Caution/Monitor. Concomitant use could result in life-threatening serotonin syndrome. If concomitant use is warranted, carefully observe the patient, particularly during treatment initiation, and during dose adjustment of the serotonergic drug. Discontinue buprenorphine if serotonin syndrome is suspected.

clomipramine increases toxicity of bupropion by unspecified interaction mechanism. Use Caution/Monitor. May lower seizure threshold; keep bupropion dose as low as possible.

butabarbital will decrease the level or effect of clomipramine by affecting hepatic enzyme CYP1A2 metabolism. Use Caution/Monitor.butabarbital will decrease the level or effect of clomipramine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely.butabarbital and clomipramine both increase sedation. Use Caution/Monitor.

butalbital will decrease the level or effect of clomipramine by affecting hepatic enzyme CYP1A2 metabolism. Use Caution/Monitor.butalbital will decrease the level or effect of clomipramine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely.butalbital and clomipramine both increase sedation. Use Caution/Monitor.

butorphanol and clomipramine both increase sedation. Use Caution/Monitor.

clomipramine increases and caffeine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

cannabidiol will increase the level or effect of clomipramine by affecting hepatic enzyme CYP2C19 metabolism. Modify Therapy/Monitor Closely. Consider reducing the dose of sensitive CYP2C19 substrates, as clinically appropriate, when coadministered with cannabidiol.

clomipramine, captopril.Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Both drugs lower blood pressure. Monitor blood pressure.

carbachol increases and clomipramine decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.

carbamazepine will decrease the level or effect of clomipramine by affecting hepatic enzyme CYP1A2 metabolism. Use Caution/Monitor.carbamazepine will decrease the level or effect of clomipramine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.

carbinoxamine and clomipramine both increase sedation. Use Caution/Monitor.

carisoprodol and clomipramine both increase sedation. Use Caution/Monitor.

celecoxib will increase the level or effect of clomipramine by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.clomipramine, celecoxib.Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. Clomipramine inhib. serotonin uptake by platelets.

cenobamate, clomipramine.Either increases effects of the other by sedation. Use Caution/Monitor.

ceritinib and clomipramine both increase QTc interval. Use Caution/Monitor.

cevimeline increases and clomipramine decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.

chloral hydrate and clomipramine both increase sedation. Use Caution/Monitor.

chlordiazepoxide and clomipramine both increase sedation. Use Caution/Monitor.

chloroquine will increase the level or effect of clomipramine by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.chloroquine increases toxicity of clomipramine by QTc interval. Use Caution/Monitor.

chlorpheniramine and clomipramine both increase sedation. Use Caution/Monitor.

chlorpromazine and clomipramine both increase sedation. Use Caution/Monitor.

chlorzoxazone and clomipramine both increase sedation. Use Caution/Monitor.

clomipramine, choline magnesium trisalicylate.Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. Clomipramine inhib. serotonin uptake by platelets.

cigarette smoking will decrease the level or effect of clomipramine by affecting hepatic enzyme CYP1A2 metabolism. Use Caution/Monitor.

cimetidine will increase the level or effect of clomipramine by affecting hepatic enzyme CYP1A2 metabolism. Use Caution/Monitor.cimetidine will increase the level or effect of clomipramine by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.cimetidine will increase the level or effect of clomipramine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.

cinnarizine and clomipramine both increase sedation. Use Caution/Monitor.

cisatracurium and clomipramine both decrease cholinergic effects/transmission. Use Caution/Monitor.

clemastine and clomipramine both increase sedation. Use Caution/Monitor.

clobazam will increase the level or effect of clomipramine by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor. Lower doses of drugs metabolized by CYP2D6 may be required when used concomitantly. clomipramine, clobazam. Other (see comment). Use Caution/Monitor. Comment: Concomitant administration can increase the potential for CNS effects (e.g., increased sedation or respiratory depression).

clonazepam and clomipramine both increase sedation. Use Caution/Monitor.

clorazepate and clomipramine both increase sedation. Use Caution/Monitor.

clozapine and clomipramine both increase sedation. Use Caution/Monitor.

cobicistat will increase the level or effect of clomipramine by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor. Carefully titrate antidepressant to the desired effect, including using the lowest feasible initial or maintenance dose, and monitoring for antidepressant responsecobicistat will increase the level or effect of clomipramine by Other (see comment). Use Caution/Monitor. Carefully titrate dose of the antidepressant to the desired effect, including using the lowest feasible initial or maintenance dose, and monitor its response during coadministration with TCAs and cobicistat.

clomipramine and cocaine topical both increase serotonin levels. Modify Therapy/Monitor Closely.

codeine and clomipramine both increase sedation. Use Caution/Monitor.clomipramine decreases effects of codeine by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor. Prevents conversion of codeine to its active metabolite morphine.

conivaptan will increase the level or effect of clomipramine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.

crizotinib and clomipramine both increase QTc interval. Use Caution/Monitor. ECG monitoring is recommended, along with drugs that may prolong the QT interval.

cyclizine and clomipramine both decrease cholinergic effects/transmission. Use Caution/Monitor.cyclizine and clomipramine both increase sedation. Use Caution/Monitor.

cyclobenzaprine and clomipramine both decrease cholinergic effects/transmission. Use Caution/Monitor.cyclobenzaprine and clomipramine both increase sedation. Use Caution/Monitor.

cyclosporine will increase the level or effect of clomipramine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.

cyproheptadine and clomipramine both increase sedation. Use Caution/Monitor.

dantrolene and clomipramine both increase sedation. Use Caution/Monitor.

clomipramine and daridorexant both increase sedation. Modify Therapy/Monitor Closely. Coadministration increases risk of CNS depression, which can lead to additive impairment of psychomotor performance and cause daytime impairment.

darifenacin will increase the level or effect of clomipramine by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.darifenacin will increase the level or effect of clomipramine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.darifenacin and clomipramine both decrease cholinergic effects/transmission. Use Caution/Monitor.

darunavir will increase the level or effect of clomipramine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.

clomipramine and dasatinib both increase QTc interval. Modify Therapy/Monitor Closely.

clomipramine decreases effects of debrisoquine by Other (see comment). Use Caution/Monitor. Comment: Inhibition of uptake by adrenergic neurons.

deferasirox increases levels of clomipramine by affecting hepatic enzyme CYP1A2 metabolism. Use Caution/Monitor.

desflurane and clomipramine both increase sedation. Use Caution/Monitor.desflurane and clomipramine both increase QTc interval. Use Caution/Monitor.

clomipramine and desipramine both decrease cholinergic effects/transmission. Use Caution/Monitor.clomipramine and desipramine both increase sedation. Use Caution/Monitor.

desvenlafaxine will increase the level or effect of clomipramine by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor. Desvenlafaxine inhibits CYP2D6; with higher desvenlafaxine doses (ie, 400 mg) decrease the CYP2D6 substrate dose by up to 50%; no dosage adjustment needed with desvenlafaxine doses <100 mg

clomipramine and deutetrabenazine both increase sedation. Use Caution/Monitor.deutetrabenazine and clomipramine both increase QTc interval. Use Caution/Monitor. At the maximum recommended dose, deutetrabenazine does not prolong QT interval to a clinically relevant extent. Certain circumstances may increase risk of torsade de pointes and/or sudden death in association with drugs that prolong the QTc interval (eg, bradycardia, hypokalemia or hypomagnesemia, coadministration with other drugs that prolong QTc interval, presence of congenital QT prolongation).

dexchlorpheniramine and clomipramine both increase sedation. Use Caution/Monitor.

clomipramine increases and dexfenfluramine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.clomipramine and dexfenfluramine both increase serotonin levels. Modify Therapy/Monitor Closely.

dexmedetomidine and clomipramine both increase sedation. Use Caution/Monitor.

clomipramine increases and dexmethylphenidate decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

clomipramine increases and dextroamphetamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.clomipramine and dextroamphetamine both increase serotonin levels. Modify Therapy/Monitor Closely.clomipramine increases effects of dextroamphetamine by unknown mechanism. Use Caution/Monitor.

clomipramine will increase the level or effect of dextroamphetamine transdermal by pharmacodynamic synergism. Modify Therapy/Monitor Closely. May enhance the activity of tricyclic or sympathomimetic agents causing striking and sustained increases in dextroamphetamine levels in brain; May be potentiate cardiovascular effects. Monitor frequently and adjust or use an alternant based on clinical response.

dextromoramide and clomipramine both increase sedation. Use Caution/Monitor.

diamorphine and clomipramine both increase sedation. Use Caution/Monitor.

diazepam and clomipramine both increase sedation. Use Caution/Monitor.

diazepam intranasal, clomipramine.Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Coadministration may potentiate the CNS-depressant effects of each drug.

dichlorphenamide and clomipramine both decrease serum potassium. Use Caution/Monitor.

clomipramine, diclofenac.Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. Clomipramine inhib. serotonin uptake by platelets.

dicyclomine and clomipramine both decrease cholinergic effects/transmission. Use Caution/Monitor.

clomipramine increases and diethylpropion decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

difelikefalin and clomipramine both increase sedation. Use Caution/Monitor.

difenoxin hcl and clomipramine both increase sedation. Use Caution/Monitor.

clomipramine, diflunisal.Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. Clomipramine inhib. serotonin uptake by platelets.

clomipramine and dihydroergotamine both increase serotonin levels. Modify Therapy/Monitor Closely.

clomipramine and dihydroergotamine intranasal both increase serotonin levels. Modify Therapy/Monitor Closely.

dimenhydrinate and clomipramine both increase sedation. Use Caution/Monitor.

diphenhydramine will increase the level or effect of clomipramine by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.diphenhydramine and clomipramine both decrease cholinergic effects/transmission. Use Caution/Monitor.diphenhydramine and clomipramine both increase sedation. Use Caution/Monitor.

diphenoxylate hcl and clomipramine both increase sedation. Use Caution/Monitor.

dipipanone and clomipramine both increase sedation. Use Caution/Monitor.

clomipramine increases and dobutamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

clomipramine and dolasetron both increase QTc interval. Modify Therapy/Monitor Closely.

donepezil increases and clomipramine decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.donepezil and clomipramine both increase QTc interval. Use Caution/Monitor.

clomipramine increases and dopamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

clomipramine increases and dopexamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

clomipramine and dosulepin both decrease cholinergic effects/transmission. Use Caution/Monitor.clomipramine and dosulepin both increase sedation. Use Caution/Monitor.

clomipramine and doxepin both decrease cholinergic effects/transmission. Use Caution/Monitor.clomipramine and doxepin both increase sedation. Use Caution/Monitor.

doxylamine and clomipramine both increase sedation. Use Caution/Monitor.

dronedarone will increase the level or effect of clomipramine by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.

droperidol and clomipramine both increase sedation. Use Caution/Monitor.

echothiophate iodide increases and clomipramine decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.

efavirenz and clomipramine both increase QTc interval. Use Caution/Monitor.

elagolix will increase the level or effect of clomipramine by affecting hepatic enzyme CYP2C19 metabolism. Modify Therapy/Monitor Closely. Elagolix is a weak CYP2C19 inhibitor. Caution with sensitive CYP2C19 substrates.

eletriptan and clomipramine both increase serotonin levels. Modify Therapy/Monitor Closely.

eliglustat increases levels of clomipramine by affecting hepatic enzyme CYP2D6 metabolism. Modify Therapy/Monitor Closely. Monitor therapeutic drug concentrations, as indicated, or consider reducing the dosage of the concomitant drug and titrate to clinical effect.eliglustat and clomipramine both increase QTc interval. Use Caution/Monitor.

elvitegravir/cobicistat/emtricitabine/tenofovir DF increases levels of clomipramine by affecting hepatic enzyme CYP2D6 metabolism. Modify Therapy/Monitor Closely. Cobicistat is a CYP2D6 inhibitor; caution with CYP2D6 substrates for which elevated plasma concentrations are associated with serious and/or life-threatening events.

entrectinib and clomipramine both increase QTc interval. Use Caution/Monitor.

clomipramine increases and ephedrine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.clomipramine increases effects of ephedrine by unknown mechanism. Use Caution/Monitor.

clomipramine increases and epinephrine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.clomipramine increases effects of epinephrine by unknown mechanism. Use Caution/Monitor.

clomipramine and epinephrine inhaled both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor. Tricyclic antidepressants may potentiate epinephrine effect on cardiovascular system.

clomipramine increases and epinephrine racemic decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.clomipramine increases effects of epinephrine racemic by unknown mechanism. Use Caution/Monitor.

clomipramine and ergotamine both increase serotonin levels. Modify Therapy/Monitor Closely.

eribulin and clomipramine both increase QTc interval. Use Caution/Monitor.

erythromycin base will increase the level or effect of clomipramine by affecting hepatic enzyme CYP1A2 metabolism. Use Caution/Monitor.

erythromycin ethylsuccinate will increase the level or effect of clomipramine by affecting hepatic enzyme CYP1A2 metabolism. Use Caution/Monitor.

erythromycin lactobionate will increase the level or effect of clomipramine by affecting hepatic enzyme CYP1A2 metabolism. Use Caution/Monitor.

erythromycin stearate will increase the level or effect of clomipramine by affecting hepatic enzyme CYP1A2 metabolism. Use Caution/Monitor.

escitalopram increases toxicity of clomipramine by QTc interval. Use Caution/Monitor.

esketamine intranasal, clomipramine.Either increases toxicity of the other by sedation. Modify Therapy/Monitor Closely.

eslicarbazepine acetate will increase the level or effect of clomipramine by affecting hepatic enzyme CYP2C19 metabolism. Use Caution/Monitor.

estazolam and clomipramine both increase sedation. Use Caution/Monitor.

clomipramine and ethanol both increase sedation. Use Caution/Monitor.

clomipramine, etodolac.Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. Clomipramine inhib. serotonin uptake by platelets.

etomidate and clomipramine both increase sedation. Use Caution/Monitor.

ezogabine, clomipramine.Either increases toxicity of the other by QTc interval. Use Caution/Monitor. Slight and transient QT-prolongation observed with ezogabine, particularly when dose titrated to 1200 mg/day. QT interval should be monitored when ezogabine is prescribed with agents known to increase QT interval.

fedratinib will increase the level or effect of clomipramine by affecting hepatic enzyme CYP2C19 metabolism. Use Caution/Monitor. Adjust dose of drugs that are CYP2C19 substrates as necessary.fedratinib will increase the level or effect of clomipramine by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor. Adjust dose of drugs that are CYP2D6 substrates as necessary.

clomipramine, fenbufen.Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. Clomipramine inhib. serotonin uptake by platelets.

clomipramine increases and fenfluramine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.clomipramine and fenfluramine both increase serotonin levels. Modify Therapy/Monitor Closely.fenfluramine, clomipramine.Either increases effects of the other by serotonin levels. Use Caution/Monitor. Coadministration with drugs that increase serotoninergic effects may increase the risk of serotonin syndrome.

clomipramine, fenoprofen.Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. Clomipramine inhib. serotonin uptake by platelets.

fesoterodine and clomipramine both decrease cholinergic effects/transmission. Use Caution/Monitor.

fexinidazole will increase the level or effect of clomipramine by affecting hepatic enzyme CYP1A2 metabolism. Use Caution/Monitor.fexinidazole will increase the level or effect of clomipramine by affecting hepatic enzyme CYP2C19 metabolism. Use Caution/Monitor.

fingolimod and clomipramine both increase QTc interval. Use Caution/Monitor.

flavoxate and clomipramine both decrease cholinergic effects/transmission. Use Caution/Monitor.

clomipramine and flecainide both increase QTc interval. Modify Therapy/Monitor Closely.

clomipramine and fluoxetine both increase QTc interval. Modify Therapy/Monitor Closely.

fluphenazine and clomipramine both increase sedation. Use Caution/Monitor.

flurazepam and clomipramine both increase sedation. Use Caution/Monitor.

clomipramine, flurbiprofen.Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. Clomipramine inhib. serotonin uptake by platelets.

fluvoxamine and clomipramine both increase QTc interval. Modify Therapy/Monitor Closely.

clomipramine increases and formoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

fosamprenavir will increase the level or effect of clomipramine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.

fosaprepitant will increase the level or effect of clomipramine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.

clomipramine and foscarnet both increase QTc interval. Modify Therapy/Monitor Closely.

fosphenytoin will decrease the level or effect of clomipramine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.

frovatriptan and clomipramine both increase serotonin levels. Modify Therapy/Monitor Closely.

gabapentin, clomipramine.Either increases effects of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Coadministration of CNS depressants can result in serious, life-threatening, and fatal respiratory depression. Use lowest dose possible and monitor for respiratory depression and sedation.

gabapentin enacarbil, clomipramine.Either increases effects of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Coadministration of CNS depressants can result in serious, life-threatening, and fatal respiratory depression. Use lowest dose possible and monitor for respiratory depression and sedation.

galantamine increases and clomipramine decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.

clomipramine and ganaxolone both increase sedation. Use Caution/Monitor.

gemifloxacin and clomipramine both increase QTc interval. Use Caution/Monitor.

gilteritinib and clomipramine both increase QTc interval. Use Caution/Monitor.

glycopyrrolate and clomipramine both decrease cholinergic effects/transmission. Use Caution/Monitor.clomipramine increases levels of glycopyrrolate by unknown mechanism. Use Caution/Monitor.

glycopyrrolate inhaled and clomipramine both decrease cholinergic effects/transmission. Use Caution/Monitor.clomipramine increases levels of glycopyrrolate inhaled by unknown mechanism. Use Caution/Monitor.

glycopyrronium tosylate topical, clomipramine.Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Coadministration of glycopyrronium tosylate topical with other anticholinergic medications may result in additive anticholinergic adverse effects.

grapefruit will increase the level or effect of clomipramine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.

haloperidol and clomipramine both increase sedation. Use Caution/Monitor.

henbane and clomipramine both decrease cholinergic effects/transmission. Use Caution/Monitor.

homatropine and clomipramine both decrease cholinergic effects/transmission. Use Caution/Monitor.

huperzine A increases and clomipramine decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.

hydrocodone, clomipramine.Either increases effects of the other by serotonin levels. Use Caution/Monitor. Coadministration of drugs that affect the serotonergic neurotransmitter system may result in serotonin syndrome. If concomitant use is warranted, carefully observe the patient, particularly during treatment initiation and dose adjustment.

hydromorphone and clomipramine both increase sedation. Use Caution/Monitor.

hydroxyzine and clomipramine both increase sedation. Use Caution/Monitor.hydroxyzine and clomipramine both increase QTc interval. Use Caution/Monitor.

hyoscyamine and clomipramine both decrease cholinergic effects/transmission. Use Caution/Monitor.

hyoscyamine spray and clomipramine both decrease cholinergic effects/transmission. Use Caution/Monitor.

clomipramine, ibuprofen.Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. Clomipramine inhib. serotonin uptake by platelets.

clomipramine, ibuprofen IV.Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. Clomipramine inhib. serotonin uptake by platelets.

clomipramine and iloperidone both increase QTc interval. Modify Therapy/Monitor Closely.iloperidone and clomipramine both increase sedation. Use Caution/Monitor.

imatinib will increase the level or effect of clomipramine by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.

clomipramine and imipramine both decrease cholinergic effects/transmission. Use Caution/Monitor.clomipramine and imipramine both increase sedation. Use Caution/Monitor.

indacaterol, inhaled, clomipramine. QTc interval. Use Caution/Monitor. Indacaterol should be administered with extreme caution to patients treated with TCAs. Drugs that are known to prolong the QTc interval may have an increased the risk of ventricular arrhythmias.

indinavir will increase the level or effect of clomipramine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.

clomipramine, indomethacin.Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. Clomipramine inhib. serotonin uptake by platelets.

ipratropium and clomipramine both decrease cholinergic effects/transmission. Use Caution/Monitor. Due to the poor systemic absorption of ipratropium, interaction unlikely at regularly recommended dosages.

isoflurane and clomipramine both increase QTc interval. Use Caution/Monitor.

isoniazid will increase the level or effect of clomipramine by affecting hepatic enzyme CYP1A2 metabolism. Use Caution/Monitor.clomipramine and isoniazid both increase serotonin levels. Modify Therapy/Monitor Closely.

clomipramine increases and isoproterenol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

itraconazole and clomipramine both increase QTc interval. Use Caution/Monitor.

ketamine and clomipramine both increase sedation. Use Caution/Monitor.

ketoconazole will increase the level or effect of clomipramine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.

clomipramine, ketoprofen.Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. Clomipramine inhib. serotonin uptake by platelets.

clomipramine, ketorolac.Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. Clomipramine inhib. serotonin uptake by platelets.

clomipramine, ketorolac intranasal.Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. Clomipramine inhib. serotonin uptake by platelets.

clomipramine and ketotifen, ophthalmic both increase sedation. Use Caution/Monitor.

clomipramine and L-tryptophan both increase serotonin levels. Modify Therapy/Monitor Closely.

clomipramine and lapatinib both increase QTc interval. Modify Therapy/Monitor Closely.

lasmiditan, clomipramine.Either increases effects of the other by sedation. Use Caution/Monitor. Coadministration of lasmiditan and other CNS depressant drugs, including alcohol have not been evaluated in clinical studies. Lasmiditan may cause sedation, as well as other cognitive and/or neuropsychiatric adverse reactions.clomipramine increases effects of lasmiditan by serotonin levels. Use Caution/Monitor. Coadministration may increase risk of serotonin syndrome.

lemborexant, clomipramine.Either increases effects of the other by sedation. Modify Therapy/Monitor Closely. Dosage adjustment may be necessary if lemborexant is coadministered with other CNS depressants because of potentially additive effects.

letermovir increases levels of clomipramine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.

clomipramine increases and levalbuterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

clomipramine and levofloxacin both increase QTc interval. Modify Therapy/Monitor Closely.

levoketoconazole will increase the level or effect of clomipramine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.

levorphanol and clomipramine both increase sedation. Use Caution/Monitor.

levothyroxine increases effects of clomipramine by Other (see comment). Use Caution/Monitor. Comment: Increased catecholamine receptor sensitivity; may increase CNS and cardiovascular effects, including arrhythmias.

liothyronine increases effects of clomipramine by Other (see comment). Use Caution/Monitor. Comment: Increased catecholamine receptor sensitivity; may increase CNS and cardiovascular effects, including arrhythmias.

liotrix increases effects of clomipramine by Other (see comment). Use Caution/Monitor. Comment: Increased catecholamine receptor sensitivity; may increase CNS and cardiovascular effects, including arrhythmias.

clomipramine increases and lisdexamfetamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.clomipramine, lisdexamfetamine.Either increases effects of the other by serotonin levels. Use Caution/Monitor. Initiate with lower doses and monitor for signs and symptoms of serotonin syndrome, particularly during initiation or dosage increase. If serotonin syndrome occurs, discontinue along with concomitant serotonergic drug(s).

clomipramine and lithium both increase serotonin levels. Modify Therapy/Monitor Closely.lithium and clomipramine both increase QTc interval. Use Caution/Monitor.

clomipramine and lofepramine both decrease cholinergic effects/transmission. Use Caution/Monitor.clomipramine and lofepramine both increase sedation. Use Caution/Monitor.

clomipramine and lofexidine both increase sedation. Use Caution/Monitor.clomipramine decreases effects of lofexidine by unspecified interaction mechanism. Use Caution/Monitor.

loprazolam and clomipramine both increase sedation. Use Caution/Monitor.

lorazepam and clomipramine both increase sedation. Use Caution/Monitor.

lorcaserin will increase the level or effect of clomipramine by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.

lormetazepam and clomipramine both increase sedation. Use Caution/Monitor.

clomipramine, lornoxicam.Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. Clomipramine inhib. serotonin uptake by platelets.

loxapine and clomipramine both increase sedation. Use Caution/Monitor.

loxapine inhaled and clomipramine both increase sedation. Use Caution/Monitor.

clomipramine and lsd both increase serotonin levels. Modify Therapy/Monitor Closely.

lumacaftor/ivacaftor, clomipramine. affecting hepatic enzyme CYP2C19 metabolism. Modify Therapy/Monitor Closely. In vitro studies suggest that lumacaftor may induce and ivacaftor may inhibit CYP2C19 substrates. .

lurasidone increases effects of clomipramine by Other (see comment). Use Caution/Monitor. Comment: Potential for increased risk of hypotension with concurrent use. Monitor blood pressure and adjust dose of antihypertensive agent as needed.

clomipramine and maprotiline both decrease cholinergic effects/transmission. Use Caution/Monitor.clomipramine and maprotiline both increase sedation. Use Caution/Monitor.

maraviroc will increase the level or effect of clomipramine by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.

marijuana will increase the level or effect of clomipramine by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.clomipramine and marijuana both increase sedation. Use Caution/Monitor.

meclizine and clomipramine both decrease cholinergic effects/transmission. Use Caution/Monitor.

clomipramine, meclofenamate.Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. Clomipramine inhib. serotonin uptake by platelets.

clomipramine, mefenamic acid.Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. Clomipramine inhib. serotonin uptake by platelets.

clomipramine and melatonin both increase sedation. Use Caution/Monitor.

clomipramine, meloxicam.Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. Clomipramine inhib. serotonin uptake by platelets.

meperidine and clomipramine both increase sedation. Use Caution/Monitor.

clomipramine and meprobamate both increase sedation. Use Caution/Monitor.

clomipramine increases and metaproterenol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

metaxalone and clomipramine both increase sedation. Use Caution/Monitor.

clomipramine and methadone both increase QTc interval. Modify Therapy/Monitor Closely.methadone and clomipramine both increase sedation. Use Caution/Monitor.

clomipramine increases and methamphetamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

methocarbamol and clomipramine both increase sedation. Use Caution/Monitor.

methscopolamine and clomipramine both decrease cholinergic effects/transmission. Use Caution/Monitor.

clomipramine increases and methylenedioxymethamphetamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

clomipramine, methylphenidate. Other (see comment). Use Caution/Monitor. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.

methylphenidate transdermal will increase the level or effect of clomipramine by decreasing elimination. Modify Therapy/Monitor Closely. Consider decreasing the dose of these drugs when given coadministered with methylphenidate. Monitor for drug toxiticities when initiating or discontinuing methylphenidate.

mexiletine will increase the level or effect of clomipramine by affecting hepatic enzyme CYP1A2 metabolism. Use Caution/Monitor.

midazolam and clomipramine both increase sedation. Use Caution/Monitor.

midazolam intranasal, clomipramine.Either increases effects of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Concomitant use of barbiturates, alcohol, or other CNS depressants may increase the risk of hypoventilation, airway obstruction, desaturation, or apnea and may contribute to profound and/or prolonged drug effect.

clomipramine increases and midodrine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

mifepristone, clomipramine. QTc interval. Modify Therapy/Monitor Closely. Use alternatives if available.

milnacipran, clomipramine. Mechanism: unspecified interaction mechanism. Use Caution/Monitor. Risk of euphoria, postural hypot'n when switching from clomipramine to milnacipran.

mirabegron will increase the level or effect of clomipramine by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.

clomipramine and mirtazapine both increase sedation. Use Caution/Monitor.clomipramine and mirtazapine both increase serotonin levels. Modify Therapy/Monitor Closely.

modafinil will decrease the level or effect of clomipramine by affecting hepatic enzyme CYP1A2 metabolism. Use Caution/Monitor.clomipramine increases and modafinil decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

morphine and clomipramine both increase sedation. Use Caution/Monitor.clomipramine and morphine both increase serotonin levels. Modify Therapy/Monitor Closely.

clomipramine and motherwort both increase sedation. Use Caution/Monitor.

clomipramine and moxonidine both increase sedation. Use Caution/Monitor.

clomipramine and nabilone both increase sedation. Use Caution/Monitor.

clomipramine, nabumetone.Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. Clomipramine inhib. serotonin uptake by platelets.

nalbuphine and clomipramine both increase sedation. Use Caution/Monitor.

clomipramine, naproxen.Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. Clomipramine inhib. serotonin uptake by platelets.

naratriptan and clomipramine both increase serotonin levels. Modify Therapy/Monitor Closely.

nefopam, clomipramine. Mechanism: unspecified interaction mechanism. Use Caution/Monitor. Use combination with caution.

nelfinavir will increase the level or effect of clomipramine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.

neostigmine increases and clomipramine decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.

nilotinib will increase the level or effect of clomipramine by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.

clomipramine increases and norepinephrine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.clomipramine increases effects of norepinephrine by unknown mechanism. Use Caution/Monitor.

clomipramine and nortriptyline both decrease cholinergic effects/transmission. Use Caution/Monitor.clomipramine and nortriptyline both increase sedation. Use Caution/Monitor.

clomipramine and ofloxacin both increase QTc interval. Modify Therapy/Monitor Closely.

olanzapine and clomipramine both increase sedation. Use Caution/Monitor.olanzapine and clomipramine both increase QTc interval. Use Caution/Monitor.

clomipramine will increase the level or effect of oliceridine by affecting hepatic enzyme CYP2D6 metabolism. Modify Therapy/Monitor Closely. If concomitant use is necessary, may require less frequent oliceridine dosing. Closely monitor for respiratory depression and sedation and titrate subsequent doses accordingly. If inhibitor is discontinued, consider increase oliceridine dosage until stable drug effects are achieved. Monitor for signs of opioid withdrawal. clomipramine, oliceridine.Either increases effects of the other by serotonin levels. Modify Therapy/Monitor Closely.clomipramine increases toxicity of oliceridine by Other (see comment). Modify Therapy/Monitor Closely. Comment: Anticholinergic drugs may increase risk of urinary retention and/or severe constipation, which may lead to paralytic ileus. Monitor for signs of urinary retention or reduced gastric motility if oliceridine is coadministered with anticholinergics.

clomipramine and olodaterol inhaled both increase QTc interval. Use Caution/Monitor. TCAs prolong the QTc interval and may potentiate the effects of beta2 agonists on the cardiovascular system; increased risk of ventricular arrhythmias

onabotulinumtoxinA and clomipramine both decrease cholinergic effects/transmission. Use Caution/Monitor.

opium tincture and clomipramine both increase sedation. Use Caution/Monitor.

clomipramine and orphenadrine both decrease cholinergic effects/transmission. Use Caution/Monitor.orphenadrine and clomipramine both increase sedation. Use Caution/Monitor.

osimertinib and clomipramine both increase QTc interval. Use Caution/Monitor. Conduct periodic monitoring with ECGs and electrolytes in patients taking drugs known to prolong the QTc interval.

clomipramine, oxaprozin.Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. Clomipramine inhib. serotonin uptake by platelets.

oxazepam and clomipramine both increase sedation. Use Caution/Monitor.

oxybutynin and clomipramine both decrease cholinergic effects/transmission. Use Caution/Monitor.

oxybutynin topical and clomipramine both decrease cholinergic effects/transmission. Use Caution/Monitor.

oxybutynin transdermal and clomipramine both decrease cholinergic effects/transmission. Use Caution/Monitor.

oxycodone and clomipramine both increase sedation. Use Caution/Monitor.

clomipramine increases effects of oxymetazoline intranasal by pharmacodynamic synergism. Use Caution/Monitor. TCAs inhibit norepinephrine uptake in adrenergic neurons, thereby increasing synaptic norepinephrine levels. Coadministration with alpha1 agonists may cause increased adrenergic receptor stimulation. When oxymetazoline is combined with intranasal tetracaine for dental anesthesia, avoid or use alternant anesthetic in patients taking TCAs.

oxymorphone and clomipramine both increase sedation. Use Caution/Monitor.

ozanimod and clomipramine both increase QTc interval. Modify Therapy/Monitor Closely. The potential additive effects on heart rate, treatment with ozanimod should generally not be initiated in patients who are concurrently treated with QT prolonging drugs with known arrhythmogenic properties.

clomipramine and paliperidone both increase QTc interval. Modify Therapy/Monitor Closely.paliperidone and clomipramine both increase sedation. Use Caution/Monitor.

pancuronium and clomipramine both decrease cholinergic effects/transmission. Use Caution/Monitor.

papaveretum and clomipramine both increase sedation. Use Caution/Monitor.

clomipramine and papaverine both increase sedation. Use Caution/Monitor.

parecoxib will increase the level or effect of clomipramine by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.clomipramine, parecoxib.Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. Clomipramine inhib. serotonin uptake by platelets.

clomipramine and paroxetine both increase QTc interval. Modify Therapy/Monitor Closely.

clomipramine and pasireotide both increase QTc interval. Modify Therapy/Monitor Closely.

clomipramine and pazopanib both increase QTc interval. Use Caution/Monitor.

peginterferon alfa 2a will increase the level or effect of clomipramine by affecting hepatic enzyme CYP1A2 metabolism. Use Caution/Monitor.

peginterferon alfa 2b, clomipramine. Other (see comment). Use Caution/Monitor. Comment: When patients are administered peginterferon alpha-2b with CYP2D6 substrates, the therapeutic effect of these drugs may be altered. Peginterferon alpha-2b may increase or decrease levels of CYP2D6 substrate.

pentazocine and clomipramine both increase sedation. Use Caution/Monitor.clomipramine and pentazocine both increase serotonin levels. Modify Therapy/Monitor Closely.

pentobarbital will decrease the level or effect of clomipramine by affecting hepatic enzyme CYP1A2 metabolism. Use Caution/Monitor.pentobarbital will decrease the level or effect of clomipramine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely.pentobarbital and clomipramine both increase sedation. Use Caution/Monitor.

perphenazine will increase the level or effect of clomipramine by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.perphenazine and clomipramine both increase sedation. Use Caution/Monitor.

clomipramine increases and phendimetrazine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

phenobarbital will decrease the level or effect of clomipramine by affecting hepatic enzyme CYP1A2 metabolism. Use Caution/Monitor.phenobarbital will decrease the level or effect of clomipramine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely.phenobarbital and clomipramine both increase sedation. Use Caution/Monitor.

clomipramine increases and phentermine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

clomipramine increases and phenylephrine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

clomipramine, phenylephrine ophthalmic. Other (see comment). Use Caution/Monitor. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.

clomipramine increases and phenylephrine PO decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor. .

phenytoin will decrease the level or effect of clomipramine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.

clomipramine and pholcodine both increase sedation. Use Caution/Monitor.

physostigmine increases and clomipramine decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.

pilocarpine increases and clomipramine decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.

pimozide and clomipramine both increase sedation. Use Caution/Monitor.

pipemidic acid will increase the level or effect of clomipramine by affecting hepatic enzyme CYP1A2 metabolism. Use Caution/Monitor.

clomipramine increases and pirbuterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

clomipramine, piroxicam.Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. Clomipramine inhib. serotonin uptake by platelets.

clomipramine and posaconazole both increase QTc interval. Modify Therapy/Monitor Closely.

pralidoxime and clomipramine both decrease cholinergic effects/transmission. Use Caution/Monitor.

pregabalin, clomipramine.Either increases effects of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Coadministration of CNS depressants can result in serious, life-threatening, and fatal respiratory depression. Use lowest dose possible and monitor for respiratory depression and sedation.

primidone will decrease the level or effect of clomipramine by affecting hepatic enzyme CYP1A2 metabolism. Use Caution/Monitor.primidone will decrease the level or effect of clomipramine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely.primidone and clomipramine both increase sedation. Use Caution/Monitor.

prochlorperazine and clomipramine both increase QTc interval. Use Caution/Monitor.prochlorperazine and clomipramine both increase sedation. Use Caution/Monitor.

promethazine and clomipramine both increase sedation. Use Caution/Monitor.

propafenone will increase the level or effect of clomipramine by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.

propantheline and clomipramine both decrease cholinergic effects/transmission. Use Caution/Monitor.

propofol and clomipramine both increase sedation. Use Caution/Monitor.

clomipramine increases and propylhexedrine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

clomipramine and protriptyline both decrease cholinergic effects/transmission. Use Caution/Monitor.clomipramine and protriptyline both increase sedation. Use Caution/Monitor.

pyridostigmine increases and clomipramine decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.

quazepam and clomipramine both increase sedation. Use Caution/Monitor.

quetiapine and clomipramine both increase sedation. Use Caution/Monitor.quetiapine, clomipramine.Either increases toxicity of the other by QTc interval. Use Caution/Monitor. Avoid use with drugs that prolong QT and in patients with risk factors for prolonged QT interval. Postmarketing cases show QT prolongation with overdose in patients with concomitant illness or with drugs known to cause electrolyte imbalance or prolong QT.

quinacrine will increase the level or effect of clomipramine by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.

clomipramine and quinine both increase QTc interval. Use Caution/Monitor.

clomipramine and ramelteon both increase sedation. Use Caution/Monitor.

ranolazine will increase the level or effect of clomipramine by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.clomipramine and ranolazine both increase QTc interval. Modify Therapy/Monitor Closely.

rapacuronium and clomipramine both decrease cholinergic effects/transmission. Use Caution/Monitor.

clomipramine, remifentanil.Either increases effects of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. May also increase risk of serotonin syndrome.

remimazolam, clomipramine.Either increases toxicity of the other by sedation. Modify Therapy/Monitor Closely. Coadministration may result in profound sedation, respiratory depression, coma, and/or death. Continuously monitor vital signs during sedation and recovery period if coadministered. Carefully titrate remimazolam dose if administered with opioid analgesics and/or sedative/hypnotics.

rifabutin will decrease the level or effect of clomipramine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.rifabutin decreases levels of clomipramine by increasing metabolism. Use Caution/Monitor.

rifampin will decrease the level or effect of clomipramine by affecting hepatic enzyme CYP1A2 metabolism. Use Caution/Monitor.rifampin will decrease the level or effect of clomipramine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.

rifapentine will decrease the level or effect of clomipramine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.

rilpivirine increases toxicity of clomipramine by QTc interval. Use Caution/Monitor. Rilpivirine should be used with caution when co-administered with a drug with a known risk of Torsades de Pointes.

clomipramine and risperidone both increase QTc interval. Modify Therapy/Monitor Closely.risperidone and clomipramine both increase sedation. Use Caution/Monitor.

ritonavir will increase the level or effect of clomipramine by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.ritonavir will increase the level or effect of clomipramine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.

rivastigmine increases and clomipramine decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.

rizatriptan and clomipramine both increase serotonin levels. Modify Therapy/Monitor Closely.

rocuronium and clomipramine both decrease cholinergic effects/transmission. Use Caution/Monitor.

rolapitant will increase the level or effect of clomipramine by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor. Rolapitant may increase plasma concentrations of CYP2D6 substrates for at least 28 days following rolapitant administration.

clomipramine and romidepsin both increase QTc interval. Modify Therapy/Monitor Closely.

clomipramine, salicylates (non-asa).Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. Clomipramine inhib. serotonin uptake by platelets.

clomipramine increases and salmeterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

clomipramine, salsalate.Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. Clomipramine inhib. serotonin uptake by platelets.

clomipramine and SAMe both increase serotonin levels. Modify Therapy/Monitor Closely.

scopolamine and clomipramine both decrease cholinergic effects/transmission. Use Caution/Monitor.

clomipramine and scullcap both increase sedation. Use Caution/Monitor.

secobarbital will decrease the level or effect of clomipramine by affecting hepatic enzyme CYP1A2 metabolism. Use Caution/Monitor.secobarbital will decrease the level or effect of clomipramine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely.secobarbital and clomipramine both increase sedation. Use Caution/Monitor.

selpercatinib increases toxicity of clomipramine by QTc interval. Use Caution/Monitor.

sertraline will increase the level or effect of clomipramine by affecting hepatic enzyme CYP2D6 metabolism. Modify Therapy/Monitor Closely.

sevoflurane and clomipramine both increase sedation. Use Caution/Monitor.sevoflurane and clomipramine both increase QTc interval. Use Caution/Monitor.

clomipramine and shepherd's purse both increase sedation. Use Caution/Monitor.

smoking will decrease the level or effect of clomipramine by affecting hepatic enzyme CYP1A2 metabolism. Use Caution/Monitor.

sodium sulfate/?magnesium sulfate/potassium chloride increases effects of clomipramine by unknown mechanism. Use Caution/Monitor. Closely monitor for evidence of seizures when using higher dose of magnesium sulfate together with drugs that lower the seizure threshold.

sodium sulfate/potassium sulfate/magnesium sulfate increases effects of clomipramine by unknown mechanism. Use Caution/Monitor. Closely monitor for evidence of seizures when using higher dose of magnesium sulfate together with drugs that lower the seizure threshold.

clomipramine, sodium sulfate/potassium sulfate/magnesium sulfate/polyethylene glycol. Other (see comment). Use Caution/Monitor. Comment: Caution when bowel preps are used with drugs that cause SIADH or NSAIDs; increased risk for water retention or electrolyte imbalance.

solifenacin and clomipramine both decrease cholinergic effects/transmission. Use Caution/Monitor.solifenacin and clomipramine both increase QTc interval. Use Caution/Monitor.

sorafenib and clomipramine both increase QTc interval. Use Caution/Monitor.

sparsentan will decrease the level or effect of clomipramine by affecting hepatic enzyme CYP2C19 metabolism. Use Caution/Monitor. Sparsentan (a CYP2C19 inducer) decreases exposure of CYP2C19 substrates and reduces efficacy related to these substrates.

St John's Wort will decrease the level or effect of clomipramine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely.

stiripentol, clomipramine. affecting hepatic enzyme CYP1A2 metabolism. Modify Therapy/Monitor Closely. Stiripentol is a CYP1A2 inhibitor and inducer. Monitor CYP1A2 substrates coadministered with stiripentol for increased or decreased effects. CYP1A2 substrates may require dosage adjustment.stiripentol will decrease the level or effect of clomipramine by affecting hepatic enzyme CYP2C19 metabolism. Modify Therapy/Monitor Closely. Consider reducing the dose of CYP2C19 substrates, if adverse reactions are experienced when administered concomitantly with stiripentol.stiripentol, clomipramine.Either increases effects of the other by sedation. Use Caution/Monitor. Concomitant use stiripentol with other CNS depressants, including alcohol, may increase the risk of sedation and somnolence.

succinylcholine increases and clomipramine decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.

sufentanil and clomipramine both increase sedation. Use Caution/Monitor.

sufentanil SL, clomipramine.Either increases effects of the other by serotonin levels. Use Caution/Monitor. Coadministration of drugs that affect the serotonergic neurotransmitter system may result in serotonin syndrome. If concomitant use is warranted, carefully observe the patient, particularly during treatment initiation and dose adjustment.

clomipramine and sulfamethoxazole both increase QTc interval. Modify Therapy/Monitor Closely.

clomipramine, sulfasalazine.Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. Clomipramine inhib. serotonin uptake by platelets.

clomipramine, sulindac.Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. Clomipramine inhib. serotonin uptake by platelets.

sumatriptan and clomipramine both increase serotonin levels. Modify Therapy/Monitor Closely.

sumatriptan intranasal and clomipramine both increase serotonin levels. Modify Therapy/Monitor Closely.

suvorexant and clomipramine both increase sedation. Modify Therapy/Monitor Closely. Dosage adjustments of suvorexant and concomitant CNS depressants may be necessary

tacrolimus and clomipramine both increase QTc interval. Use Caution/Monitor.

clomipramine increases levels of tamsulosin by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.

tapentadol and clomipramine both increase sedation. Use Caution/Monitor.clomipramine and tapentadol both increase serotonin levels. Modify Therapy/Monitor Closely.

tecovirimat will increase the level or effect of clomipramine by affecting hepatic enzyme CYP2C19 metabolism. Use Caution/Monitor. Tecovirimat is a weak inhibitor of CYP2C8 and CYP2C19. Monitor for adverse effects if coadministered with sensitive substrates of these enzymes.

clomipramine and telavancin both increase QTc interval. Modify Therapy/Monitor Closely.

temazepam and clomipramine both increase sedation. Use Caution/Monitor.

terbinafine will increase the level or effect of clomipramine by affecting hepatic enzyme CYP2D6 metabolism. Modify Therapy/Monitor Closely. Assess need to reduce dose of CYP2D6-metabolized drug.

clomipramine increases and terbutaline decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

teriflunomide decreases levels of clomipramine by affecting hepatic enzyme CYP1A2 metabolism. Use Caution/Monitor.

tetrabenazine and clomipramine both increase QTc interval. Use Caution/Monitor.

thioridazine and clomipramine both increase sedation. Use Caution/Monitor.

thiothixene and clomipramine both increase sedation. Use Caution/Monitor.

thyroid desiccated increases effects of clomipramine by Other (see comment). Use Caution/Monitor. Comment: Increased catecholamine receptor sensitivity; may increase CNS and cardiovascular effects, including arrhythmias.

tiotropium and clomipramine both decrease cholinergic effects/transmission. Use Caution/Monitor.

tipranavir will increase the level or effect of clomipramine by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.

tobacco use will decrease the level or effect of clomipramine by affecting hepatic enzyme CYP1A2 metabolism. Use Caution/Monitor.

clomipramine, tolfenamic acid.Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. Clomipramine inhib. serotonin uptake by platelets.

clomipramine, tolmetin.Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. Clomipramine inhib. serotonin uptake by platelets.

tolterodine and clomipramine both decrease cholinergic effects/transmission. Use Caution/Monitor.

clomipramine and topiramate both increase sedation. Modify Therapy/Monitor Closely.

tramadol and clomipramine both increase sedation. Use Caution/Monitor.clomipramine and tramadol both increase serotonin levels. Modify Therapy/Monitor Closely.

clomipramine and trazodone both decrease cholinergic effects/transmission. Use Caution/Monitor.clomipramine and trazodone both increase sedation. Use Caution/Monitor.

triazolam and clomipramine both increase sedation. Use Caution/Monitor.

triclabendazole will increase the level or effect of clomipramine by affecting hepatic enzyme CYP2C19 metabolism. Use Caution/Monitor. If plasma concentrations of the CYP2C19 substrates are elevated during triclabendazole, recheck plasma concentration of the CYP2C19 substrates after discontinuation of triclabendazole.

triclofos and clomipramine both increase sedation. Use Caution/Monitor.

trifluoperazine and clomipramine both increase sedation. Use Caution/Monitor.

trihexyphenidyl and clomipramine both decrease cholinergic effects/transmission. Use Caution/Monitor. Potential for additive anticholinergic effects.

clomipramine and trimethoprim both increase QTc interval. Modify Therapy/Monitor Closely.

clomipramine and trimipramine both decrease cholinergic effects/transmission. Use Caution/Monitor.clomipramine and trimipramine both increase sedation. Use Caution/Monitor.

triprolidine and clomipramine both increase sedation. Use Caution/Monitor.

clomipramine and tropisetron both increase QTc interval. Modify Therapy/Monitor Closely.

trospium chloride and clomipramine both decrease cholinergic effects/transmission. Use Caution/Monitor.

valbenazine and clomipramine both increase QTc interval. Use Caution/Monitor.

valerian and clomipramine both increase sedation. Use Caution/Monitor.

vecuronium and clomipramine both decrease cholinergic effects/transmission. Use Caution/Monitor.

venlafaxine will increase the level or effect of clomipramine by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.clomipramine and venlafaxine both increase QTc interval. Modify Therapy/Monitor Closely.

verapamil will increase the level or effect of clomipramine by affecting hepatic enzyme CYP1A2 metabolism. Use Caution/Monitor.

voclosporin, clomipramine.Either increases effects of the other by QTc interval. Use Caution/Monitor.

clomipramine and voriconazole both increase QTc interval. Modify Therapy/Monitor Closely.

clomipramine increases and xylometazoline decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

clomipramine increases and yohimbine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

clomipramine and ziconotide both increase sedation. Use Caution/Monitor.

zileuton will increase the level or effect of clomipramine by affecting hepatic enzyme CYP1A2 metabolism. Use Caution/Monitor.

ziprasidone and clomipramine both increase sedation. Use Caution/Monitor.

zolmitriptan and clomipramine both increase serotonin levels. Modify Therapy/Monitor Closely.

clomipramine increases effects of acarbose by pharmacodynamic synergism. Minor/Significance Unknown.

amobarbital, clomipramine. Other (see comment). Minor/Significance Unknown. Comment: Barbiturates may increase adverse effects, including respiratory depression, produced by toxic doses of TCAs. With therapeutic doses of TCAs, barbiturates increase metabolism and decrease blood concentrations of TCAs.

armodafinil will decrease the level or effect of clomipramine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.

artemether/lumefantrine will decrease the level or effect of clomipramine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.

clomipramine increases levels of atropine by unknown mechanism. Minor/Significance Unknown.

clomipramine increases levels of atropine IV/IM by unknown mechanism. Minor/Significance Unknown.

bazedoxifene/conjugated estrogens, clomipramine. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Estrogens and progestins may decr tricyclic antidepressant effects, while increasing TCA plasma concentration and adverse effects.

bosentan will decrease the level or effect of clomipramine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.

clomipramine decreases effects of brimonidine by pharmacodynamic antagonism. Minor/Significance Unknown.

budesonide will decrease the level or effect of clomipramine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.

butabarbital, clomipramine. Other (see comment). Minor/Significance Unknown. Comment: Barbiturates may increase adverse effects, including respiratory depression, produced by toxic doses of TCAs. With therapeutic doses of TCAs, barbiturates increase metabolism and decrease blood concentrations of TCAs.

butalbital, clomipramine. Other (see comment). Minor/Significance Unknown. Comment: Barbiturates may increase adverse effects, including respiratory depression, produced by toxic doses of TCAs. With therapeutic doses of TCAs, barbiturates increase metabolism and decrease blood concentrations of TCAs.

carbamazepine decreases levels of clomipramine by increasing metabolism. Minor/Significance Unknown.

clomipramine, chlorpromazine.Either increases levels of the other by decreasing metabolism. Minor/Significance Unknown. Additive anticholinergic effects.clomipramine, chlorpromazine.Either increases levels of the other by pharmacodynamic synergism. Minor/Significance Unknown. Additive anticholinergic effects.

clomipramine increases effects of chlorpropamide by pharmacodynamic synergism. Minor/Significance Unknown.

conjugated estrogens, clomipramine. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Estrogens and progestins may decr tricyclic antidepressant effects, while increasing TCA plasma concentration and adverse effects.

conjugated estrogens, vaginal, clomipramine. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Estrogens and progestins may decr tricyclic antidepressant effects, while increasing TCA plasma concentration and adverse effects.

cortisone will decrease the level or effect of clomipramine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.

desflurane, clomipramine. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Risk of arrhythmias or hypotension.

dexamethasone will decrease the level or effect of clomipramine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.

dexmethylphenidate increases effects of clomipramine by decreasing metabolism. Minor/Significance Unknown.

DHEA, herbal will increase the level or effect of clomipramine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.

efavirenz will decrease the level or effect of clomipramine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.

eslicarbazepine acetate will decrease the level or effect of clomipramine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.

esomeprazole will increase the level or effect of clomipramine by affecting hepatic enzyme CYP2C19 metabolism. Minor/Significance Unknown.

estradiol, clomipramine. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Estrogens and progestins may decr tricyclic antidepressant effects, while increasing TCA plasma concentration and adverse effects.

estrogens conjugated synthetic, clomipramine. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Estrogens and progestins may decr tricyclic antidepressant effects, while increasing TCA plasma concentration and adverse effects.

estrogens esterified, clomipramine. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Estrogens may inhibit hepatic metabolism of tricyclic antidepressants. However, interactions are not common.

estropipate, clomipramine. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Estrogens and progestins may decr tricyclic antidepressant effects, while increasing TCA plasma concentration and adverse effects.

ethinylestradiol will increase the level or effect of clomipramine by affecting hepatic enzyme CYP1A2 metabolism. Minor/Significance Unknown.

etomidate, clomipramine. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Risk of arrhythmias or hypotension.

etravirine will decrease the level or effect of clomipramine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.

clomipramine and eucalyptus both increase sedation. Minor/Significance Unknown.

fludrocortisone will decrease the level or effect of clomipramine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.

clomipramine, fluphenazine.Either increases levels of the other by decreasing metabolism. Minor/Significance Unknown. Additive anticholinergic effects.clomipramine, fluphenazine.Either increases levels of the other by pharmacodynamic synergism. Minor/Significance Unknown. Additive anticholinergic effects.

clomipramine increases effects of glimepiride by pharmacodynamic synergism. Minor/Significance Unknown.

clomipramine increases effects of glipizide by pharmacodynamic synergism. Minor/Significance Unknown.

clomipramine increases effects of glyburide by pharmacodynamic synergism. Minor/Significance Unknown.

griseofulvin will decrease the level or effect of clomipramine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.

hydrocortisone will decrease the level or effect of clomipramine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.

hydroxyprogesterone caproate (DSC), clomipramine. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Estrogens and progestins may decr tricyclic antidepressant effects, while increasing TCA plasma concentration and adverse effects.

clomipramine increases effects of insulin aspart by pharmacodynamic synergism. Minor/Significance Unknown.

clomipramine increases effects of insulin detemir by pharmacodynamic synergism. Minor/Significance Unknown.

clomipramine increases effects of insulin glargine by pharmacodynamic synergism. Minor/Significance Unknown.

clomipramine increases effects of insulin glulisine by pharmacodynamic synergism. Minor/Significance Unknown.

clomipramine increases effects of insulin lispro by pharmacodynamic synergism. Minor/Significance Unknown.

clomipramine increases effects of insulin NPH by pharmacodynamic synergism. Minor/Significance Unknown.

clomipramine increases effects of insulin regular human by pharmacodynamic synergism. Minor/Significance Unknown.

isoniazid will increase the level or effect of clomipramine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.

isoproterenol, clomipramine. Mechanism: unknown. Minor/Significance Unknown. Risk of cardiac arrhythmias.

itraconazole will increase the level or effect of clomipramine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.

ketamine, clomipramine. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Risk of arrhythmias or hypotension.

lithium, clomipramine. Other (see comment). Minor/Significance Unknown. Comment: Risk of neurotoxicity in geriatric pts. Multiple mechanisms involved.

lumefantrine will decrease the level or effect of clomipramine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.

marijuana will increase the level or effect of clomipramine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.

mestranol, clomipramine. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Estrogens and progestins may decr tricyclic antidepressant effects, while increasing TCA plasma concentration and adverse effects.

clomipramine increases effects of metformin by pharmacodynamic synergism. Minor/Significance Unknown.

methylprednisolone will decrease the level or effect of clomipramine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.

metronidazole will increase the level or effect of clomipramine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.

miconazole vaginal will increase the level or effect of clomipramine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.

clomipramine increases effects of miglitol by pharmacodynamic synergism. Minor/Significance Unknown.

clomipramine increases effects of nateglinide by pharmacodynamic synergism. Minor/Significance Unknown.

nevirapine will decrease the level or effect of clomipramine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.

nifedipine will increase the level or effect of clomipramine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.

nilotinib will increase the level or effect of clomipramine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.

omeprazole will increase the level or effect of clomipramine by affecting hepatic enzyme CYP2C19 metabolism. Minor/Significance Unknown.

oxcarbazepine will decrease the level or effect of clomipramine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.

panax ginseng increases effects of clomipramine by pharmacodynamic synergism. Minor/Significance Unknown.

pentobarbital, clomipramine. Other (see comment). Minor/Significance Unknown. Comment: Barbiturates may increase adverse effects, including respiratory depression, produced by toxic doses of TCAs. With therapeutic doses of TCAs, barbiturates increase metabolism and decrease blood concentrations of TCAs.

clomipramine, perphenazine.Either increases levels of the other by decreasing metabolism. Minor/Significance Unknown. Additive anticholinergic effects.clomipramine, perphenazine.Either increases levels of the other by pharmacodynamic synergism. Minor/Significance Unknown. Additive anticholinergic effects.

phenobarbital, clomipramine. Other (see comment). Minor/Significance Unknown. Comment: Barbiturates may increase adverse effects, including respiratory depression, produced by toxic doses of TCAs. With therapeutic doses of TCAs, barbiturates increase metabolism and decrease blood concentrations of TCAs.

clomipramine increases effects of pioglitazone by pharmacodynamic synergism. Minor/Significance Unknown.

pleurisy root decreases effects of clomipramine by unspecified interaction mechanism. Minor/Significance Unknown. Theoretical interaction.

posaconazole will increase the level or effect of clomipramine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.

prednisone will decrease the level or effect of clomipramine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.

primidone, clomipramine. Other (see comment). Minor/Significance Unknown. Comment: Barbiturates may increase adverse effects, including respiratory depression, produced by toxic doses of TCAs. With therapeutic doses of TCAs, barbiturates increase metabolism and decrease blood concentrations of TCAs.

clomipramine, prochlorperazine.Either increases levels of the other by decreasing metabolism. Minor/Significance Unknown. Additive anticholinergic effects.clomipramine, prochlorperazine.Either increases levels of the other by pharmacodynamic synergism. Minor/Significance Unknown. Additive anticholinergic effects.

progesterone micronized, clomipramine. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Estrogens and progestins may decr tricyclic antidepressant effects, while increasing TCA plasma concentration and adverse effects.

clomipramine, promazine.Either increases levels of the other by decreasing metabolism. Minor/Significance Unknown. Additive anticholinergic effects.clomipramine, promazine.Either increases levels of the other by pharmacodynamic synergism. Minor/Significance Unknown. Additive anticholinergic effects.

clomipramine, promethazine.Either increases levels of the other by decreasing metabolism. Minor/Significance Unknown. Additive anticholinergic effects.clomipramine, promethazine.Either increases levels of the other by pharmacodynamic synergism. Minor/Significance Unknown. Additive anticholinergic effects.

propofol, clomipramine. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Risk of arrhythmias or hypotension.

quinupristin/dalfopristin will increase the level or effect of clomipramine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.

clomipramine increases effects of repaglinide by pharmacodynamic synergism. Minor/Significance Unknown.

clomipramine increases effects of rosiglitazone by pharmacodynamic synergism. Minor/Significance Unknown.

rufinamide will decrease the level or effect of clomipramine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.

clomipramine and sage both increase sedation. Minor/Significance Unknown.

clomipramine increases effects of saxagliptin by pharmacodynamic synergism. Minor/Significance Unknown.

secobarbital, clomipramine. Other (see comment). Minor/Significance Unknown. Comment: Barbiturates may increase adverse effects, including respiratory depression, produced by toxic doses of TCAs. With therapeutic doses of TCAs, barbiturates increase metabolism and decrease blood concentrations of TCAs.

serdexmethylphenidate/dexmethylphenidate increases effects of clomipramine by decreasing metabolism. Minor/Significance Unknown.

sevoflurane, clomipramine. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Risk of arrhythmias or hypotension.

clomipramine increases effects of sitagliptin by pharmacodynamic synergism. Minor/Significance Unknown.

sulfamethoxazole decreases levels of clomipramine by unspecified interaction mechanism. Minor/Significance Unknown.

clomipramine, thioridazine.Either increases levels of the other by decreasing metabolism. Minor/Significance Unknown. Additive anticholinergic effects.clomipramine, thioridazine.Either increases levels of the other by pharmacodynamic synergism. Minor/Significance Unknown. Additive anticholinergic effects.

clomipramine increases effects of tolazamide by pharmacodynamic synergism. Minor/Significance Unknown.

clomipramine increases effects of tolbutamide by pharmacodynamic synergism. Minor/Significance Unknown.

topiramate will decrease the level or effect of clomipramine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.

clomipramine, trifluoperazine.Either increases levels of the other by decreasing metabolism. Minor/Significance Unknown. Additive anticholinergic effects.clomipramine, trifluoperazine.Either increases levels of the other by pharmacodynamic synergism. Minor/Significance Unknown. Additive anticholinergic effects.

clomipramine increases effects of vasopressin by pharmacodynamic synergism. Minor/Significance Unknown.

verapamil will increase the level or effect of clomipramine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.verapamil increases levels of clomipramine by decreasing metabolism. Minor/Significance Unknown.

clomipramine increases effects of vildagliptin by pharmacodynamic synergism. Minor/Significance Unknown.

voriconazole will increase the level or effect of clomipramine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.

zafirlukast will increase the level or effect of clomipramine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.

zolpidem, clomipramine.Either increases effects of the other by pharmacodynamic synergism. Minor/Significance Unknown. Additive CNS depression.